GSK1278863

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2016
02420122016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Decreased erythropoietin (EPO) production, shortened erythrocyte survival, and other factors reducing the response to EPO… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2016
2016
Hypoxia-inducible factor prolyl hydroxylase inhibitors stabilize levels of hypoxia-inducible factor that upregulate transcription… (More)
Is this relevant?
2016
2016
BACKGROUND Anemia associated with chronic kidney disease (CKD) often requires treatment with recombinant human erythropoietin… (More)
Is this relevant?
2016
2016
Drug candidates, which have the potential of enhancing athletic performance represent a risk of being misused in elite sport… (More)
Is this relevant?
2016
2016
GSK1278863 is an investigative drug under investigation for treatment of anemia associated with chronic kidney disease. Its… (More)
Is this relevant?
2016
2016
suggest that oral hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitors might be effective therapies for anaemia in… (More)
Is this relevant?
2015
2015
This study was performed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of GSK1278863, a novel prolyl… (More)
Is this relevant?
2014
2014
Hypoxia inducible factor (HIF) stabilization by HIF-prolyl hydroxylase (PHD) inhibitors may improve ischemic conditions such as… (More)
Is this relevant?
2014
2014
Anemia, a frequent complication of chronic kidney disease, is most commonly treated with recombinant human erythropoiesis… (More)
Is this relevant?
Review
2012
Review
2012
Increasing the blood's capacity for oxygen transport by erythropoiesis-stimulating agents (ESAs) constitutes a prohibited… (More)
Is this relevant?